References
- 1. Zicht op zinnige en duurzame zorg. Zoetermeer: Raad voor de Volksgezondheid en Zorg, 2006.
- 2. College voor zorgverzekeringen (since 2014 Zorginstituut Nederland). Diemen 2012. Report assessment health outcomes research alglucosidase alfa (Myozyme®) for Pompe disease. Diemen: CVZ; 2012. http://www.cvz.nl/binaries/live/%20cvzinternet/hst_content/nl/documenten/rapporten/2012/rpt211-ziekte-van-pompe.pdf.
- 3. College voor zorgverzekeringen (since 2014 Zorginstituut Nederland). Diemen 2012. Report assessment health outcomes research agalsidase alfa (Replagal®) and agalsidase bèta (Fabrazyme®) for Fabry disease. Diemen: CVZ; 2012. http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/rapporten/2012/rpt1211-ziekte-van-fabry.pdf.
- 4. Letter of Ministry of Health 29 January 2013. The Netherlands.
- 5. Letter of Ministry of Health 3 October 2013. The Netherlands.
- 6. National Institute for Health and Care Excellence. Appraising Orphan Drugs. Last updated: 14 April 2008. www.nice.org.uk/aboutnice/whoweare/seniormanagementteam/meetings/2005/12july2005/appraising_orphan_drugs.jsp; www.nice.org.uk/niceMedia/pdf/smt/120705item4.pdf.
- 7. Hutton J, Rutten FFH, Hasselt van P, Oosterwijk C, Dubois D, Nuijten MJC. Economic relevance and validation procedure. Orphan Medicinal Products. Munich, 28 February 2014, ISBN: 978-94-91526-04-6.
- 8. Rabinovich, M., Greenberg, D. and Shemer, J.(2007). Threshold values for cost-effectiveness ratio and public funding of medical technologies. Harefuah 146, 453-458, 500.
- 9. Nuijten MJ, Dubois DJ. Cost-utility analysis: current methodological issues and future perspectives. Front Pharmacol 2011. Jun 8;2:29. doi: 10.3389/fphar.2011.00029. eCollection 2011.
- 10. http://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&mid=WC0b01a
- 11. European Medicines Agency. EPAR Myozyme. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000636/WC500032128.pdf
- 12. Acquadro C, Berzon R, Dubois D. Incorporating the Patient’s Perspective into Drug Development and Communication: An Ad Hoc Task Force Report of the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001. Value in Health. Volume 6, Number 5, 2003, 522-531.
- 13. EUnetHTA JA1 WP5 methodology guidelines Endpoints used for relative effectiveness assessment of pharmaceuticals HEALTHRELATED QUALITY OF LIFE and UTILITY MEASURES. February 2013.
- 14. Sussex J, Rollet P, Garau M et al. Multi-Criteria Decision Analysis to Value Orphan Medicines. Research Paper 13/03. OHE. May 2013.
- 15. Deverka PA et al. Economic Opportunities and Challenges for Pharmacogenomics; Annual Revue of Pharmacology and Toxicology 50: 423-37, 2010.10.1146/annurev.pharmtox.010909.105805